Original scientific paper
https://doi.org/10.20471/LO.2021.49.01.02
Tolerability of bevacizumab in elderly patients with ovarian cancer: an experience from the Department of Gynecologic Oncology in the University Hospital Centre Zagreb
Kristina Katić
; Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital Centre Zagreb, Croatia
Višnja Matković
; Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital Centre Zagreb, Croatia
Joško Lešin
; Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital Centre Zagreb, Croatia
Goran Vujić
; Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital Centre Zagreb, Croatia
Ante Ćorušić
; Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital Centre Zagreb, Croatia
Abstract
Introduction: Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody. It is an effective treatment for epithelial ovarian cancer, both in primary and recurrent disease. The incidence of ovarian cancer increases with advancing age. Despite the high prevalence of the ovarian cancer in elderly, the management of these patients is often less aggressive than in younger patients. In Croatia, from February 2017, we have opportunity to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in the first-line and second-line settings. Our aim was to investigate the safety of bevacizumab administration in patients older than 65 years.
Methods: We have retrospectively analyzed the archive data of 65 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who started treatment with bevacizumab in primary advanced and in first relapse setting at the Department of Gynecologic Oncology in the University Hospital Centre Zagreb in the period from January 2017 to December 2018. Patients were divided in two categories according to age: group 1 (≤65 years) and group 2 (>65 years).
Results: Our analysis included 65 patients:47 (72.3%) patients in group 1 compared with 18 (27.7%) in group 2. Bevacizumab was administered to 39 (60%) patients as first-line treatment and to 26 (40%) patients as second-line treatment. The median age was 70 years (range 66-76 years) in group 2 and 55 years (range 35-65 years) in group 1. ECOG status 0 had 44.7% of patients in group 1 compared with only 22% in group 2. At the time of diagnosis, elderly patients had presented with at least one comorbidity in 94.4% of the cases, compared with 42.6% in group 1. The median number of cycles of bevacizumab was 9 in elderly patients and 17 cycles in group 1. Among those patients receiving bevacizumab in the first-line setting, median progression free interval (PFI) was 12 months in younger patients versus 7 months in elderly patients. Similarly, among those receiving bevacizumab in the second-line setting PFI was 9 months in younger patients versus 1 months in elderly patients. The occurrence of non-hematological adverse events did not increase in elderly patients; 51.1% of patients in group 1 reported some of non-hematological adverse events versus only 27.8% in elderly patients.
Conclusion: Our experience in treating patients with bevacizumab shows good results with acceptable toxicity and our findings suggest that its use in the elderly population should be considered as safe and manageable.
Keywords
ovary cancer; bevacizumab; therapy; elderly patients
Hrčak ID:
257749
URI
Publication date:
25.5.2021.
Visits: 1.225 *